Rowasa
Rowasa Brand names, Rowasa Analogs
Rowasa Brand Names Mixture
- No information avaliable
Rowasa Chemical_Formula
C6H11NO3
Rowasa RX_link
No information avaliable
Rowasa fda sheet
Rowasa msds (material safety sheet)
Rowasa Synthesis Reference
No information avaliable
Rowasa Molecular Weight
145.156 g/mol
Rowasa Melting Point
No information avaliable
Rowasa H2O Solubility
Freely soluble
Rowasa State
Solid
Rowasa LogP
-1.026
Rowasa Dosage Forms
Cream for topical administration (160 mg/g of methyl aminolevulinate equivalent to 16.0% of methyl aminolevulinate)
Rowasa Indication
For topical use, in combination with 570 to 670 nm wavelength red light illumination, in the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette).
Rowasa Pharmacology
After topical application of methyl aminolevulinate, porphyrins will accumulate intracellularly in the treated skin lesions. The intracellular porphyrins (including PpIX) are photoactive, fluorescing compounds and, upon light activation in the presence of oxygen, singlet oxygen is formed which causes damage to cellular compartments, in particular the mitochondria. Light activation of accumulated porphyrins leads to a photochemical reaction and thereby phototoxicity to the light-exposed target cells.
Rowasa Absorption
In vitro, after 24 hours the mean cumulative absorption through human skin was 0.26% of the administered dose.
Rowasa side effects and Toxicity
The severity of local phototoxic reactions such as erythema, pain and burning sensation may increase in case of prolonged application time or very high light intensity.
Rowasa Patient Information
Rowasa Organisms Affected
Humans and other mammals
